Table 2.
Details of the disease stage, chemotherapy treatment and disease outcome of the 11 rectal cancer patients of our validation cohort
| Patient | Stage | Neo-adjuvant therpay | RCPATH | Outcome |
|---|---|---|---|---|
| 1 | III | 50.4/28 + 5FU | A | Good |
| 2 | III | 54.0/30 + 5FU | A | Good |
| 3 | III | 50.4/28 + 5FU | A | Good |
| 4 | II | 50.4/28 + 5FU | A | Good |
| 5 | III | 50.4/28 + 5FU | B | Poor |
| 6 | III | 50.4/28 + 5FU | B | Poor |
| 7 | III | 50.4/28 + 5FU | B | Poor |
| 8 | III | 50.4/28 + 5FU | B | Poor |
| 9 | III | 50.4/28 + 5FU | C | Poor |
| 10 | III | 50.4/28 + 5FU | C | Poor |
| 11 | II | 50.4/28 + 5FU | C | Poor |
5FU 5-fluorouracil; 50.4/28, total amount of 50.4 Gy radiotherapy in 28 fractions